Health Blueprint

Back to Longevity News

News summary

BioCardia completes PMDA consultations for CardiAMP in Japan

Source: Longevity Technology • Published: 09 Nov 2026, 16:46

Summarized by Masters of Longevity from Longevity Technology.

Company finished PMDA clinical consultations and plans marketing application submission.

BioCardia completes PMDA consultations for CardiAMP in Japan
Key Takeaways
  • BioCardia finished PMDA consultations and will seek approval.
  • CardiAMP is a catheter-delivered autologous therapy for ischemic heart failure.
  • Clinical evaluation included over 200 procedures and randomized trials.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.